Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nautilus Biotechnology filings document SEC reporting for a Nasdaq-listed life sciences tools company developing single-molecule proteome analysis technology. Recent Form 8-K reports furnish quarterly and annual financial results and record material events, including continued-listing compliance with Nasdaq rules.
Proxy materials cover annual meeting procedures, director elections, stockholder voting matters, and board governance. The filings also identify the company's registered common stock under ticker NAUT and provide formal records of its capital structure, governance actions, and public-company reporting obligations.
Andreessen Horowitz-affiliated funds filed Amendment No. 2 to a Schedule 13D for Nautilus Biotechnology, Inc. after a June 26, 2026 block trade at $2.00 per share.
AH Bio Fund II, L.P. now reports beneficial ownership of 8,366,966 common shares, or 6.6%, and Andreessen Horowitz LSV Fund II, L.P. reports 696,088 shares, or 0.5%. Marc Andreessen and Benjamin Horowitz each report shared beneficial ownership of 9,063,054 shares, or 7.1%, based on 127,078,855 common shares outstanding as of April 23, 2026.
Nautilus Biotechnology director Matthew L. Posard received a grant of stock options for 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036. According to the grant terms, one-twelfth of the option vests each month after the grant date, so long as he continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan.
Nautilus Biotechnology director Farzad Nazem received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036. All 45,000 options are held directly after this grant.
According to the grant’s terms, one-twelfth of the options vest each month following the grant date, as long as Nazem continues to serve as a “Service Provider” under Nautilus’s 2021 Equity Incentive Plan. This creates a 12‑month, time-based vesting schedule tied to ongoing service.
Nautilus Biotechnology, Inc. director Karen Akinsanya received a grant of stock options as part of her compensation. The award covers 45,000 options to buy common stock at an exercise price of $2.28 per share, expiring on June 18, 2036.
These options vest in equal monthly installments over 12 months following the grant date, as long as she continues as a qualifying “Service Provider” under the company’s 2021 Equity Incentive Plan. After this grant, she holds 45,000 stock options directly.
Nautilus Biotechnology director Matthew S. McIlwain received a grant of stock options for 45,000 shares of common stock. These options have an exercise price of $2.28 per share and expire on June 18, 2036. Following this grant, he holds options for 45,000 shares directly.
The options were awarded as compensation, not purchased in the open market, and vest over time. One-twelfth of the options vest each month after the grant date as long as he continues to serve as a qualifying service provider to the company.
Nautilus Biotechnology director Melissa B. Epperly received a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $2.28 per share and expire on June 18, 2036.
These options vest in equal monthly installments over 12 months, with one-twelfth of the grant vesting each month after the grant date, as long as she continues to serve as a “Service Provider” under the company’s 2021 Equity Incentive Plan. Following this grant, she holds 45,000 stock options directly.
Nautilus Biotechnology, Inc. reported the results of its 2026 annual stockholder meeting held on June 17, 2026. Of 127,078,855 common shares outstanding as of April 20, 2026, 85,002,191 were represented in person or by proxy, indicating strong participation.
Stockholders elected Class II directors Parag Mallick and Farzad Nazem, each to serve until the 2029 annual meeting. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026.
In an advisory vote, stockholders approved the 2025 executive compensation program and expressed a preference to hold future advisory votes on executive pay every one year. The company plans to conduct annual Say on Pay votes until the next required frequency vote, scheduled no later than the 2032 annual meeting.
Andreessen Horowitz–affiliated funds filed an amended Schedule 13D for Nautilus Biotechnology to reflect recent share sales and updated holdings. AH Bio Fund II and Andreessen Horowitz LSV Fund II sold 4,615,974 and 384,026 Nautilus common shares, respectively, on June 2, 2026 in a single block trade at $2.35 per share.
After these transactions, Marc Andreessen and Benjamin Horowitz are each reported to beneficially own 12,653,917 shares, representing approximately 9.96% of Nautilus’s common stock based on 127,078,855 shares outstanding as of April 23, 2026, though EDGAR cover pages round this to 9.9%. The filing details their sole and shared voting and dispositive powers through various venture funds and general partner entities.
Nautilus Biotechnology, Inc. disclosed that investment funds affiliated with Andreessen Horowitz executed open-market sales of common stock. AH Bio Fund II, L.P. sold 4,615,974 shares of common stock at $2.35 per share, leaving 11,682,032 shares of common stock held indirectly. Andreessen Horowitz LSV Fund II, L.P. sold 384,026 shares of common stock at $2.35 per share, with 971,885 shares of common stock remaining indirectly held. The funds are controlled through general partners AH Equity Partners Bio II, L.L.C. and AH Equity Partners LSV II, L.L.C., whose managing members are Marc Andreessen and Ben Horowitz, and the reporting persons disclaim group status and beneficial ownership beyond any pecuniary interest.